Published in Neurol Sci on January 04, 2008
Cardiovascular actions of neurotrophins. Physiol Rev (2009) 1.45
Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev (2011) 1.09
Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J Clin Invest (2010) 0.94
Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities. Neuropathol Appl Neurobiol (2011) 0.81
The endocannabinoid system and sex steroid hormone-dependent cancers. Int J Endocrinol (2013) 0.77
TrkC expression predicts favorable clinical outcome in invasive ductal carcinoma of breast independent of NT-3 expression. Am J Cancer Res (2014) 0.75
Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress. Cancers (Basel) (2010) 0.75
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med (2000) 2.85
Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J (1991) 2.23
Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer (2002) 1.87
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest (2003) 1.61
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A (1998) 1.53
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res (2001) 1.49
Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res (2004) 1.45
Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse (2004) 1.42
A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res (2004) 1.41
Inhibition of tumor angiogenesis by cannabinoids. FASEB J (2003) 1.36
Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology (2000) 1.34
A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer (2006) 1.24
Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res (2004) 1.15
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J (2003) 1.15
De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J (2002) 1.13
Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma. J Biosci (2003) 1.10
Brain metastases in melanoma: roles of neurotrophins. Neuro Oncol (2004) 1.07
Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res (1999) 1.02
Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem (2002) 0.98
Paracrine control of vascularization and neurogenesis by neurotrophins. Br J Pharmacol (2003) 0.96
Trk A, B, and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma. Acta Neuropathol (1998) 0.93
Nestin expression in reactive astrocytes of human pathology. J Neurooncol (2006) 0.89
Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol (2005) 0.87
Mitogenesis in glioblastoma multiforme cell lines: a role for NGF and its TrkA receptors. J Neurooncol (1999) 0.87
Cannabinoid receptors in human astroglial tumors. J Neurochem (2006) 0.85
Neurotrophic factor expression in childhood low-grade astrocytomas and ependymomas. Childs Nerv Syst (2004) 0.83
Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology (2004) 0.83
Growth control of C6 glioma in vivo by nerve growth factor. J Neurooncol (2002) 0.82
delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem (2001) 0.80
Rat cerebral endothelial cells express trk C and are regulated by neurotrophin-3. Biochem Biophys Res Commun (2003) 0.80
Differentiation and growth inhibition of glioma cells induced by transfer of trk A proto-oncogene. J Neurooncol (1999) 0.78
Control of proliferation and survival of C6 glioma cells with modification of the nerve growth factor autocrine system. J Neurooncol (1999) 0.76
TrkA induces differentiation but not apoptosis in C6-2B glioma cells. J Neurosci Res (2001) 0.75
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (2006) 7.69
Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med (2000) 3.51
Supratentorial cavernous angiomas and epileptic seizures: preoperative course and postoperative outcome. Neurosurgery (1996) 2.29
Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology (1999) 2.27
Long-term follow-up of bilateral hypothalamic stimulation for intractable cluster headache. Brain (2004) 2.27
Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med (1992) 2.15
Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene (2009) 1.85
Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet (1999) 1.76
Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology (2003) 1.60
Cervical myelopathy caused by hypoplasia of the atlas: two case reports and review of the literature. Neurosurgery (1998) 1.51
Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol (1994) 1.50
Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med (2001) 1.49
Peripheral nerve involvement in Churg-Strauss syndrome. J Neurol (1992) 1.44
Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. Neurology (2007) 1.40
Pallidal stimulation for acquired dystonia due to cerebral palsy: beyond 5 years. Eur J Neurol (2014) 1.39
Low frequency of NF1 gene mutations in malignant gliomas. Eur J Cancer (1993) 1.39
Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene (2006) 1.37
L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology (2004) 1.36
Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol (2011) 1.34
Surgical treatment of spasticity in cerebral palsy. Childs Brain (1978) 1.28
hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer (2005) 1.24
Validation of Italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry (1999) 1.21
Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol (2008) 1.18
Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry (2005) 1.17
Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol (2005) 1.15
Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.15
Huge epidural hematoma after surgery for spinal cord stimulation. Acta Neurochir (Wien) (2005) 1.15
Study of the excitability cycle of the blink reflex in Huntington's chorea. Eur Neurol (1976) 1.13
Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch A Pathol Anat Histopathol (1991) 1.13
Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow-up. Neurol Sci (2003) 1.13
Pain syndrome and focal myokymia due to anterior interosseous neurovascular relationships: report of a case and neurophysiological considerations. J Neurosurg (1995) 1.11
Deep brain stimulation for intractable chronic cluster headache: proposals for patient selection. Cephalalgia (2004) 1.11
Free cytoplasmic Ca++ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology (1988) 1.10
Lycopersicon esculentum lectin: an effective and versatile endothelial marker of normal and tumoral blood vessels in the central nervous system. Eur J Histochem (2005) 1.10
Quality of life in brain tumor patients. J Neurooncol (1996) 1.06
Cerebral cavernomas and seizures: a retrospective study on 163 patients who underwent pure lesionectomy. Neurol Sci (2006) 1.06
Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet (1996) 1.05
Endothelium and the brain in CNS lupus. Lupus (2003) 1.05
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer (2009) 1.05
Histologic prognostic factors in ependymoma. Childs Nerv Syst (1991) 1.03
Isolated diaphragmatic tremor: is there a spectrum in "respiratory myoclonus"? Neurology (2007) 1.02
Lessons from 8 years' experience of hypothalamic stimulation in cluster headache. Cephalalgia (2008) 1.01
Delayed examination of synovial fluid by ordinary and polarised light microscopy to detect and identify crystals. Ann Rheum Dis (2002) 1.01
Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med (1994) 1.01
Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol (2000) 1.00
Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm (2001) 1.00
Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc (2005) 1.00
Self-closing Nitinol U-Clips for intracranial arterial microanastomosis: a preliminary experience on seven cases. Acta Neurochir (Wien) (2009) 0.99
A case of posttraumatic tremor treated by chronic stimulation of the thalamus. Mov Disord (1993) 0.98
Primary glial tumor patients treated by combining cis-platin and etoposide. J Neurooncol (1991) 0.97
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother (1993) 0.97
Reversal of thalamic hand syndrome by long-term motor cortex stimulation. J Neurosurg (2000) 0.97
Headache in brain tumours: a symptom to reappraise critically. Neurol Sci (2004) 0.97
Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral preamyloid deposits. Neurosci Lett (1990) 0.96
Spontaneous neuronal activity of the posterior hypothalamus in trigeminal autonomic cephalalgias. Neurol Sci (2007) 0.95
Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD. Parkinsonism Relat Disord (2012) 0.95
Beta PP participates in PrP-amyloid plaques of Gerstmann-Sträussler-Scheinker disease, Indiana kindred. J Neuropathol Exp Neurol (1993) 0.95
Costs of hypothalamic stimulation in chronic drug-resistant cluster headache: preliminary data. Neurol Sci (2009) 0.95
The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther (1995) 0.94
Cognitive impairment and quality of life in long-term survivors of malignant brain tumors. Ital J Neurol Sci (1994) 0.93
Stereotactic biopsy of deep brain tumors in infancy and childhood. Childs Brain (1983) 0.93
Value of serial stereotactic biopsies and impedance monitoring in the treatment of deep brain tumours. J Neurol Neurosurg Psychiatry (1981) 0.93
Mandibular implant-retained overdenture: finite element analysis of two anchorage systems. Int J Oral Maxillofac Implants (1998) 0.92
Long-term results of percutaneous retrogasserian thermorhizotomy for "essential" trigeminal neuralgia: considerations in 1000 consecutive patients. Neurosurgery (1990) 0.92
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives. J Hypertens (2001) 0.92
A study of the activity of platelet monoamine oxidase in patients with migraine headaches or with 'cluster headaches'. Eur Neurol (1977) 0.92
A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol (1993) 0.91
A modified visual analogue scale for the assessment of chronic pain. Neurol Sci (2011) 0.91
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother (1994) 0.91
Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol (1994) 0.91
Intravascular lymphomatosis (IL) in a child mimicking a posterior fossa tumor. J Neurooncol (2001) 0.90
Corticosteroids protect oligodendrocytes from cytokine-induced cell death. Neuroreport (2000) 0.90
Neurogenic muscle hypertrophy. Report of two cases. J Neurol (1989) 0.90
Immunocompetence of human microvascular brain endothelial cells: cytokine regulation of IL-1beta, MCP-1, IL-10, sICAM-1 and sVCAM-1. J Neurol (1998) 0.90
CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neurooncol (2005) 0.89